Schedule 13G ownership disclosure
UNICYCIVE THERAPEUTICS INC
Common Stock, $0.001 par value per share · CUSIP: 90466Y103
Event date: 2025-03-31
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Vivo Opportunity Fund Holdings, L.P.
Shares: 60,961,729.00 · Class: 9.99%
- Vivo Opportunity, LLC
Shares: 60,961,729.00 · Class: 9.99%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001213900-25-043719
- Form type
- SCHEDULE 13G/A
- Filer
- Unicycive Therapeutics, Inc.
- CIK
- CIK 1766140
- Filed
- May 15, 2025
- Reporting period
- Mar 31, 2025
- Description
- Schedule 13G beneficial ownership